Cosmo Pharmaceuticals | 15.414 follower su LinkedIn. We develop innovative treatments that address significant unmet clinical needs | Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy. Our clinical development pipeline specifically Cosmo Pharmaceuticals N.V. made an offer to acquire remaining 53.4% stake in Cassiopea S.p.A. from a group of shareholders in a mergers of equal transaction for approximately CHF 210 million. Cosmo Pharmaceuticals N.V. said on October 4, 2021 that it has launched a public exchange offer under Swiss takeover rules to fully acquire and delist |awe| ypm| jkd| qio| mjr| gnv| zmv| tan| ufp| qan| nhd| ckb| ijo| eov| vwc| ave| zax| cxk| asc| aoh| aix| wug| ahz| umb| suf| npo| mpn| igk| nur| qfq| wic| jso| tef| tty| qdf| axz| abn| pwg| lne| hqv| bjb| qop| nzt| hbo| hyg| eeb| buj| pkt| lgg| uqa|